These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 35919538)

  • 1. Performance of a Standardized Clinical Assay for Urinary C-C Motif Chemokine Ligand 14 (CCL14) for Persistent Severe Acute Kidney Injury.
    Koyner JL; Chawla LS; Bihorac A; Gunnerson KJ; Schroeder R; Demirjian S; Hodgson L; Frey JA; Wilber ST; Kampf JP; Kwan T; McPherson P; Kellum JA;
    Kidney360; 2022 Jul; 3(7):1158-1168. PubMed ID: 35919538
    [TBL] [Abstract][Full Text] [Related]  

  • 2. External validation of urinary C-C motif chemokine ligand 14 (CCL14) for prediction of persistent acute kidney injury.
    Bagshaw SM; Al-Khafaji A; Artigas A; Davison D; Haase M; Lissauer M; Zacharowski K; Chawla LS; Kwan T; Kampf JP; McPherson P; Kellum JA
    Crit Care; 2021 May; 25(1):185. PubMed ID: 34059102
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessing the role of Chemokine (C-C motif) ligand 14 in AKI: a European consensus meeting.
    Koyner JL; Arndt C; Baldira Martinez de Irujo J; Coelho S; Garcia-Montesinos de la Peña M; di Girolamo L; Joannidis M; Jorge-Monjas P; Koch C; Lobaz S; Meyer A; Ostermann M; Pertica N; Prowle JR; Silversides J; Zarbock A; Echeverri J; Harenski K; Forni LG
    Ren Fail; 2024 Dec; 46(1):2345747. PubMed ID: 38666354
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification and validation of biomarkers of persistent acute kidney injury: the RUBY study.
    Hoste E; Bihorac A; Al-Khafaji A; Ortega LM; Ostermann M; Haase M; Zacharowski K; Wunderink R; Heung M; Lissauer M; Self WH; Koyner JL; Honore PM; Prowle JR; Joannidis M; Forni LG; Kampf JP; McPherson P; Kellum JA; Chawla LS;
    Intensive Care Med; 2020 May; 46(5):943-953. PubMed ID: 32025755
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive performance of two types of urinary biomarkers for renal non-recovery in sepsis-associated acute kidney injury: a prospective observational study.
    Licheng ; Jia H; Jiang Y; Li W
    BMC Nephrol; 2024 May; 25(1):153. PubMed ID: 38702662
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictability performance of urinary C-C motif chemokine ligand 14 and renal resistive index for persistent sepsis-associated acute kidney injury in ICU patients.
    Jiang W; Liao T; Yu J; Shao J; Zheng R
    Int Urol Nephrol; 2023 Aug; 55(8):1995-2003. PubMed ID: 36797554
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of urinary C-C motif chemokine ligand 14 (CCL14) and first-generation urinary biomarkers for predicting renal recovery from acute kidney injury: a prospective exploratory study.
    Qian BS; Jia HM; Weng YB; Li XC; Chen CD; Guo FX; Han YZ; Huang LF; Zheng Y; Li WX
    J Intensive Care; 2023 Mar; 11(1):11. PubMed ID: 36941674
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Towards a Better Crystal Ball: Urinary C-C Motif Chemokine Ligand 14 (CCL14) and Persistent Severe AKI.
    Belcher JM
    Kidney360; 2022 Jul; 3(7):1124-1127. PubMed ID: 35919534
    [No Abstract]   [Full Text] [Related]  

  • 9. Performance of urinary C-C motif chemokine ligand 14 for the prediction of persistent acute kidney injury: a systematic review and meta-analysis.
    Chen YT; Pan HC; Hsu CK; Sun CY; Chen CY; Chen YH; Hsu HJ; Wu IW; Wu VC; Hoste E
    Crit Care; 2023 Aug; 27(1):318. PubMed ID: 37596698
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predicting the Development of Renal Replacement Therapy Indications by Combining the Furosemide Stress Test and Chemokine (C-C Motif) Ligand 14 in a Cohort of Postsurgical Patients.
    Meersch M; Weiss R; Gerss J; Albert F; Gruber J; Kellum JA; Chawla L; Forni LG; Koyner JL; von Groote T; Zarbock A
    Crit Care Med; 2023 Aug; 51(8):1033-1042. PubMed ID: 36988335
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serial Urinary C-C Motif Chemokine Ligand 14 and Risk of Persistent Severe Acute Kidney Injury.
    Prowle JR; Artigas A; Bagshaw SM; Forni LG; Heung M; Hoste E; Marlies O; Koyner JL; Chawla L; Kampf JP; Kwan T; McPherson P; Kellum JA
    Crit Care Explor; 2023 Mar; 5(3):e0870. PubMed ID: 36875557
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of C-C motif chemokine ligand 14 with other biomarkers for adverse kidney events after cardiac surgery.
    Massoth C; Küllmar M; Enders D; Kellum JA; Forni LG; Meersch M; Zarbock A;
    J Thorac Cardiovasc Surg; 2023 Jan; 165(1):199-207.e2. PubMed ID: 33832791
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CCL14 testing to guide clinical practice in patients with AKI: Results from an international expert panel.
    Kellum JA; Bagshaw SM; Demirjian S; Forni L; Joannidis M; Kampf JP; Koyner JL; Kwan T; McPherson P; Ostermann M; Prowle J; Ronco C; de la Salle J; Schneider A; Tolwani A; Zarbock A
    J Crit Care; 2024 Aug; 82():154816. PubMed ID: 38678981
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exploring the Cost-Utility of a Biomarker Predicting Persistent Severe Acute Kidney Injury: The Case of C-C Motif Chemokine Ligand 14 (CCL14).
    Echeverri J; Martins R; Harenski K; Kampf JP; McPherson P; Textoris J; Koyner JL
    Clinicoecon Outcomes Res; 2024; 16():1-12. PubMed ID: 38235419
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimal cut points of plasma and urine neutrophil gelatinase-associated lipocalin for the prediction of acute kidney injury among critically ill adults: retrospective determination and clinical validation of a prospective multicentre study.
    Tecson KM; Erhardtsen E; Eriksen PM; Gaber AO; Germain M; Golestaneh L; Lavoria MLA; Moore LW; McCullough PA
    BMJ Open; 2017 Jul; 7(7):e016028. PubMed ID: 28698338
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CCL14 Predicts Oliguria and Dialysis Requirement in Patients with Moderate to Severe Acute Kidney Injury.
    Demirjian S; Chawla L; Davison D; Forni LG; Heung M; Hoste EAJ; Koyner J; Kampf JP; Kwan T; McPherson P; Kellum JA
    Blood Purif; 2024; 53(7):548-556. PubMed ID: 38636476
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Early vs Delayed Initiation of Renal Replacement Therapy on Mortality in Critically Ill Patients With Acute Kidney Injury: The ELAIN Randomized Clinical Trial.
    Zarbock A; Kellum JA; Schmidt C; Van Aken H; Wempe C; Pavenstädt H; Boanta A; Gerß J; Meersch M
    JAMA; 2016 May 24-31; 315(20):2190-9. PubMed ID: 27209269
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biomarker Predictors of Adverse Acute Kidney Injury Outcomes in Critically Ill Patients: The Dublin Acute Biomarker Group Evaluation Study.
    McMahon BA; Galligan M; Redahan L; Martin T; Meaney E; Cotter EJ; Murphy N; Hannon C; Doran P; Marsh B; Nichol A; Murray PT
    Am J Nephrol; 2019; 50(1):19-28. PubMed ID: 31203271
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Interleukin-18 combined with kidney injury molecule-1 predict 28-day mortality in patients with acute kidney injury treated with continuous renal replacement therapy in intensive care unit].
    Huo Y; Zhang K; Hu Z
    Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2019 Jul; 31(7):832-836. PubMed ID: 31441405
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Derivation and validation of urinary TIMP-1 for the prediction of acute kidney injury and mortality in critically ill children.
    Huang H; Lin Q; Dai X; Chen J; Bai Z; Li X; Fang F; Li Y
    J Transl Med; 2022 Feb; 20(1):102. PubMed ID: 35197070
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.